Skip to content
4 min read Trial Tuesday trial-tuesday

Trial Tuesday: Obesity's Next Tier Steps Up

Viking bets on fewer shots, while Roche bets on a better-engineered molecule, as both chase the next generation of obesity blockbusters.

an image of a person running on a hilly terrain with the sun setting in the background
The race for the next obesity blockbuster is an uphill climb. Photo by Venti Views on Unsplash

It’s another Tuesday, and another edition where we discuss the obesity treatment paradigm. The battle to become the next generation of obesity blockbusters is heating up, and we look at two different strategies being pursued by two future upstarts.

Viking Bets On Fewer Injections

Viking Therapeutics is now trying to carve out space not by matching efficacy but by differentiating, with the latest data on its GLP-1/GIP receptor agonist, VK2735, showing that the injectable drug can maintain weight loss with less-frequent, every-two-week dosing.

Investors have been optimistic on VK2735 for months, given strong efficacy data from earlier trials, but some of that has been tempered since due to concerns around perceived elevated treatment-discontinuation rates. The company is also developing an oral version of the injection.

Loving Capsul? Help us share the word. We put a lot into every edition. Refer Capsul News to someone who'd find it valuable, get a shoutout in our newsletter, and the top two referrers each win a gift card. Refer a friend

In the Phase I trial, patients took the drug weekly for about five months and then switched to a shot every other week. They kept nearly all of their weight loss, far more than patients who were switched to placebo. The trial also tested a higher weekly dose over a longer period.